The reporter learned from Jingtai Technology that the company reached a cooperation agreement with the French pharmaceutical company Pierre Faber Group. The two sides will jointly carry out multiple R&D projects in the field of oncology, use Jingtai Technology's “AI+ robot” technology to design novel small molecule drugs from scratch for undisclosed targets, and jointly promote the discovery of clinical drug candidates. The cooperation is expected to expand into fields such as skin diseases and rare diseases in the future. According to the agreement, Jingtai Technology will be responsible for drug design and delivery, while Pill Faber Group will be responsible for compound screening and subsequent clinical and commercial development. The transaction includes a down payment, multiple milestone payments, and subsequent revenue shares.

The reporter learned from Jingtai Technology that the company reached a cooperation agreement with the French pharmaceutical company Pierre Faber Group. The two sides will jointly carry out multiple R&D projects in the field of oncology, use Jingtai Technology's “AI+ robot” technology to design novel small molecule drugs from scratch for undisclosed targets, and jointly promote the discovery of clinical drug candidates. The cooperation is expected to expand into fields such as skin diseases and rare diseases in the future. According to the agreement, Jingtai Technology will be responsible for drug design and delivery, while Pill Faber Group will be responsible for compound screening and subsequent clinical and commercial development. The transaction includes a down payment, multiple milestone payments, and subsequent revenue shares.